MX2022006846A - Conjugados y metodos para tratar la fibrosis hepatica. - Google Patents
Conjugados y metodos para tratar la fibrosis hepatica.Info
- Publication number
- MX2022006846A MX2022006846A MX2022006846A MX2022006846A MX2022006846A MX 2022006846 A MX2022006846 A MX 2022006846A MX 2022006846 A MX2022006846 A MX 2022006846A MX 2022006846 A MX2022006846 A MX 2022006846A MX 2022006846 A MX2022006846 A MX 2022006846A
- Authority
- MX
- Mexico
- Prior art keywords
- conjugates
- liver fibrosis
- methods
- treating liver
- double stranded
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01051—3 (or 17)-Beta-hydroxysteroid dehydrogenase (1.1.1.51)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962944963P | 2019-12-06 | 2019-12-06 | |
| PCT/US2020/063617 WO2021113820A1 (en) | 2019-12-06 | 2020-12-07 | Conjugates and methods for treating liver fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022006846A true MX2022006846A (es) | 2022-10-21 |
Family
ID=76222671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022006846A MX2022006846A (es) | 2019-12-06 | 2020-12-07 | Conjugados y metodos para tratar la fibrosis hepatica. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220387600A1 (https=) |
| EP (1) | EP4069276A4 (https=) |
| JP (1) | JP2023505434A (https=) |
| KR (1) | KR20220112788A (https=) |
| CN (1) | CN115884984A (https=) |
| AU (1) | AU2020398708A1 (https=) |
| BR (1) | BR112022010613A2 (https=) |
| CA (1) | CA3163911A1 (https=) |
| IL (1) | IL293560A (https=) |
| MX (1) | MX2022006846A (https=) |
| NZ (1) | NZ788988A (https=) |
| WO (1) | WO2021113820A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3020585A1 (en) * | 2016-04-11 | 2017-10-19 | Arbutus Biopharma Corporation | Targeted nucleic acid conjugate compositions |
| CN118234862A (zh) * | 2021-09-08 | 2024-06-21 | 阿利戈斯治疗公司 | 经修饰的短干扰核酸分子(siNA)及其用途 |
| WO2024175062A1 (zh) * | 2023-02-23 | 2024-08-29 | 大睿生物医药科技(上海)有限公司 | 调控KHK基因活性的dsRNA分子 |
| US20240352464A1 (en) * | 2023-03-07 | 2024-10-24 | Aligos Therapeutics, Inc. | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof |
| CN119219716A (zh) * | 2023-06-30 | 2024-12-31 | 上海维申医药有限公司 | 新型GalNAc的靶向递送片段及其制备和应用 |
| WO2025255972A1 (zh) * | 2024-06-13 | 2025-12-18 | 广州必贝特医药股份有限公司 | 用于靶向递送寡核苷酸药物的化合物、缀合物及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3020585A1 (en) * | 2016-04-11 | 2017-10-19 | Arbutus Biopharma Corporation | Targeted nucleic acid conjugate compositions |
| MX2019012280A (es) * | 2017-04-11 | 2020-01-23 | Arbutus Biopharma Corp | Composiciones dirigidas. |
| WO2019051257A2 (en) * | 2017-09-11 | 2019-03-14 | Arbutus Biopharma Corporation | METHODS OF TREATING HEPATITIS B TYPE INFECTIONS |
| AU2019239971B2 (en) * | 2018-03-21 | 2025-09-11 | Regeneron Pharmaceuticals, Inc. | 17beta-hydroxysteroid dehydrogenase type 13 (HSD17b13) iRNA compositions and methods of use thereof |
| EP3873530A4 (en) * | 2018-11-02 | 2022-11-09 | Genevant Sciences GmbH | THERAPEUTIC PROCESSES |
-
2020
- 2020-12-07 AU AU2020398708A patent/AU2020398708A1/en active Pending
- 2020-12-07 JP JP2022532614A patent/JP2023505434A/ja active Pending
- 2020-12-07 US US17/782,901 patent/US20220387600A1/en active Pending
- 2020-12-07 NZ NZ788988A patent/NZ788988A/en unknown
- 2020-12-07 IL IL293560A patent/IL293560A/en unknown
- 2020-12-07 EP EP20896461.9A patent/EP4069276A4/en active Pending
- 2020-12-07 MX MX2022006846A patent/MX2022006846A/es unknown
- 2020-12-07 KR KR1020227020501A patent/KR20220112788A/ko not_active Ceased
- 2020-12-07 CN CN202080091946.7A patent/CN115884984A/zh active Pending
- 2020-12-07 CA CA3163911A patent/CA3163911A1/en active Pending
- 2020-12-07 BR BR112022010613A patent/BR112022010613A2/pt not_active IP Right Cessation
- 2020-12-07 WO PCT/US2020/063617 patent/WO2021113820A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| IL293560A (en) | 2022-08-01 |
| NZ788988A (en) | 2026-02-27 |
| US20220387600A1 (en) | 2022-12-08 |
| EP4069276A4 (en) | 2025-10-08 |
| EP4069276A1 (en) | 2022-10-12 |
| BR112022010613A2 (pt) | 2022-08-16 |
| JP2023505434A (ja) | 2023-02-09 |
| CN115884984A (zh) | 2023-03-31 |
| CA3163911A1 (en) | 2021-06-10 |
| AU2020398708A1 (en) | 2022-07-14 |
| WO2021113820A1 (en) | 2021-06-10 |
| KR20220112788A (ko) | 2022-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022006846A (es) | Conjugados y metodos para tratar la fibrosis hepatica. | |
| PH12019502333A1 (en) | Targeted compositions | |
| MX2019015047A (es) | Nucleasas guiadas por acidos nucleicos. | |
| CL2022003788A1 (es) | Moléculas de unión contra bcma y usos de las mismas | |
| PH12019500626A1 (en) | Aav treatment of huntington's disease | |
| ZA201806861B (en) | Targeted nucleic acid conjugate compositions | |
| MX2021003554A (es) | Proteinas de union a dll3 y metodos de uso. | |
| MX2018016393A (es) | Conjugados para la edición de la superficie de la celula diana. | |
| CO2018012099A2 (es) | Composiciones y métodos para programar células terapéuticas utilizando nanoportadores de ácidos nucleicos dirigidos | |
| EA201900561A1 (ru) | Конъюгаты циклодекстрин-белок-лекарственное средство | |
| JOP20210142A1 (ar) | تركيبات rnai لتثبيط التعبير الوراثي عن pnpla3 وطرق استخدامها | |
| BR112021015477A2 (pt) | Anticorpos anti-cd228 e conjugados anticorpo-fármaco | |
| MX2017011298A (es) | Métodos para tratar cáncer que albergan la pérdida hemicigota de tp53. | |
| EA201691384A2 (ru) | Конструкции варианта sirp-альфа и их применение | |
| BR112018072716A2 (pt) | molécula de ácido nucleico, composição, e, métodos para tratar uma doença e para prevenir ou tratar a formação de um biofilme. | |
| EA202091520A1 (ru) | Композиции на основе irna против бокса-1 высокомобильной группы (hmgb1) и способы их применения | |
| BR112022004809A2 (pt) | Compostos 2-amino-s6-tiopurina substituídos como inibidores da proteína enpp1 | |
| WO2021081420A3 (en) | Conjugates and methods for treating acromegaly | |
| CA3241897A1 (en) | Crosslinking antibodies | |
| EA201992411A1 (ru) | Направленные композиции | |
| EA202190819A1 (ru) | Способы направленной вставки днк в гены | |
| AR111637A1 (es) | Composiciones dirigidas | |
| EA201892299A1 (ru) | Композиции конъюгата направленной нуклеиновой кислоты | |
| EA202191761A1 (ru) | Новые конъюгированные молекулы нуклеиновой кислоты и их применение | |
| CY1117039T1 (el) | Τροποποιηση της εκφρασης toy hsp47 |